Santen Pharmaceutical measures to combat the disease caused by the novel coronavirus (COVID-19) Posted Apr 1, 2020
Intravitreal VEGF Inhibitor EYLEA approved as a Treatment of Neovascular Glaucoma (NVG), its fifth indication Posted Mar 25, 2020
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration Posted Mar 10, 2020
Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020) Posted Mar 5, 2020
Beware of Suspicious E-mails and Messages on Social Media Claiming to be from Santen Pharmaceutical Co., Ltd. Posted Feb 27, 2020
Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices Posted Feb 4, 2020
Santen Pharmaceutical Selected as Title Sponsor of IBSA Blind Football World Grand Prix 2020! Posted Jan 23, 2020
Santen Pharmaceutical Signs Partnership Agreement with ITU Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology Posted Jan 10, 2020
